Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Although no therapies are approved for light chain (AL) amyloidosis, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is considered standard of care. Based on outcomes of daratumumab in multiple myeloma (MM), the phase 3 ANDROMEDA study (NCT03201965) is evaluating daratumumab-CyBorD vs CyBor...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood
Autori principali: Palladini, Giovanni, Kastritis, Efstathios, Maurer, Mathew S., Zonder, Jeffrey, Minnema, Monique C., Wechalekar, Ashutosh D., Jaccard, Arnaud, Lee, Hans C., Bumma, Naresh, Kaufman, Jonathan L., Medvedova, Eva, Kovacsovics, Tibor, Rosenzweig, Michael, Sanchorawala, Vaishali, Qin, Xiang, Vasey, Sandra Y., Weiss, Brendan M., Vermeulen, Jessica, Merlini, Giampaolo, Comenzo, Raymond L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2020
Soggetti:
Clinical Trials and Observations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7332897/
https://ncbi.nlm.nih.gov/pubmed/32244252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019004460
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi